Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

COSTEM 2023 | IFM-2015-03: plerixafor before salvage ASCT in R/R myeloma

Christian Chabannon • 21 Oct 2023
COSTEM 2023
Multiple Myeloma Plerixafor

Christian Chabannon, MD, PhD, Institut Paoli Calmettes, Marseille, France, discusses the use of plerixafor before salvage autologous stem cell transplantation (ASCT) in patients with relapsed/refractory (R/R) multiple myeloma. This interview took place at The 8th Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM 2023), held in Berlin, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Christian Chabannon

1:41
The consequences of regulatory changes on access to devices and reagents needed for graft processing
Christian Chabannon • 16 Apr 2024
2:17
Improving access to advanced therapies: the access to CAR-T in Europe
Christian Chabannon • 17 Feb 2024
1:33
Addressing the changing needs for ad-hoc resources for safe delivery of advanced therapies
Christian Chabannon • 17 Feb 2024
2:21
Practical considerations for DLI after haploidentical SCT
Christian Chabannon • 21 Oct 2023

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals